Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases.
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Aerie Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AERI has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AERI underperformed the US Pharmaceuticals industry which returned 7.7% over the past year.
Return vs Market: AERI underperformed the US Market which returned 9.2% over the past year.
Price Volatility Vs. Market
How volatile is Aerie Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StHere's Why Aerie Pharmaceuticals (NASDAQ:AERI) Can Manage Its Debt Despite Losing Money
2 months ago | Simply Wall StIs Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) CEO Being Overpaid?
3 months ago | Simply Wall StAerie Pharmaceuticals, Inc. Just Released Its Annual Results And Analysts Are Updating Their Estimates
Is Aerie Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AERI ($15.18) is trading below our estimate of fair value ($126.25)
Significantly Below Fair Value: AERI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AERI is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: AERI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AERI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AERI is overvalued based on its PB Ratio (5.5x) compared to the US Pharmaceuticals industry average (3.6x).
How is Aerie Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AERI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AERI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AERI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AERI's revenue (39.4% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: AERI's revenue (39.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AERI's Return on Equity is forecast to be high in 3 years time
How has Aerie Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AERI is currently unprofitable.
Growing Profit Margin: AERI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AERI is unprofitable, and losses have increased over the past 5 years at a rate of -27.3% per year.
Accelerating Growth: Unable to compare AERI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AERI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.5%).
Return on Equity
High ROE: AERI has a negative Return on Equity (-157.82%), as it is currently unprofitable.
How is Aerie Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AERI's short term assets ($338.4M) exceed its short term liabilities ($79.1M).
Long Term Liabilities: AERI's short term assets ($338.4M) exceed its long term liabilities ($205.9M).
Debt to Equity History and Analysis
Debt Level: AERI's debt to equity ratio (152.4%) is considered high.
Reducing Debt: AERI's debt to equity ratio has reduced from 257.1% to 152.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AERI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AERI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Aerie Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AERI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AERI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AERI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AERI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AERI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vince Anido (66yo)
Dr. Vicente J. Anido, Jr., Ph.D., also known as Vince, has been the Chairman of Aerie Pharmaceuticals, Inc. since April 4, 2013 and its Chief Executive Officer since July 25, 2013. Dr. Anido is employed at ...
CEO Compensation Analysis
Compensation vs Market: Vince's total compensation ($USD5.53M) is above average for companies of similar size in the US market ($USD3.13M).
Compensation vs Earnings: Vince's compensation has been consistent with company performance over the past year.
|CEO & Chairman||6.92yrs||US$5.53m||0.49% $3.4m|
|President & COO||6.83yrs||US$2.79m||0.17% $1.2m|
|Co-Founder & Chief Scientific Officer||15.42yrs||US$1.97m||0.47% $3.3m|
|CFO, Secretary & Treasurer||7.67yrs||US$2.47m||0.74% $5.2m|
|General Counsel & Assistant Secretary||2.33yrs||US$2.52m||0.070% $496.7k|
|Director of Accounting||1yr||no data||no data|
|Director of Investor Relations||1.42yrs||no data||no data|
|VP & Chief Compliance Officer||0.67yr||no data||no data|
|Head of Communications||2.33yrs||no data||no data|
|Vice President of Marketing||no data||no data||no data|
Experienced Management: AERI's management team is considered experienced (2.3 years average tenure).
|CEO & Chairman||6.92yrs||US$5.53m||0.49% $3.4m|
|Independent Director||6.83yrs||US$331.75k||0.078% $547.2k|
|Lead Independent Director||no data||US$354.25k||0.017% $122.2k|
|Independent Director||1.75yrs||US$326.23k||0.0081% $56.9k|
|Independent Director||6.75yrs||US$329.25k||0.036% $251.3k|
|Independent Director||5yrs||US$324.25k||0.014% $96.4k|
|Independent Director||5.08yrs||US$321.75k||0.014% $96.4k|
|Independent Director||5yrs||US$326.75k||0.014% $96.4k|
Experienced Board: AERI's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AERI insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Aerie Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aerie Pharmaceuticals, Inc.
- Ticker: AERI
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$705.388m
- Shares outstanding: 46.47m
- Website: https://www.aeriepharma.com
Number of Employees
- Aerie Pharmaceuticals, Inc.
- 4301 Emperor Boulevard
- Suite 400
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AERI||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Oct 2013|
|0P0||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2013|
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/04 04:31|
|End of Day Share Price||2020/06/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.